Дэвид Лок: Avastin и Lucentis — комиссарам NHS пора действовать рационально, ограничивая выбор для пациентов с влажной формой AMD — The BMJ
Автор
David Lock: Avastin and Lucentis—It’s time for NHS commissioners to act rationally by limiting the choices for wet AMD patients - The BMJ
David Lock: Avastin and Lucentis—It’s time for NHS commissioners to act rationally by limiting the choices for wet AMD patients
September 26, 2014
The news that a Cochrane Review has concluded that Avastin (bevacizumab) is as safe as Lucentis (ranibizumab) to treat patients with wet age related macular degeneration (“wet AMD”), along with other studies that have shown the two drugs have broadly the same level of clinical effectiveness, comes as no surprise to those of us who have been involved in this debate for a number of years.
Дальше — с подпиской Awamed+
Осталось ещё 19 абзацев. Подписка открывает материал целиком вместе с оригиналом, рисунками и файлами.